| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7
Liposome entrapment of doxorubicin has been shown to reduce its cardiotoxicity in vivo and increase its therapeutic index. A further improvement in therapeutic index could be achieved through targeting of liposome-entrapped drug selectively to cancer cells. Monoclonal antibodies against the squamous lung cancer cell line KLN-205 have been ligated to the surface of long-circulating (Stealth) and conventional liposomes. The antibody-bearing liposomes showed specific, competitive uptake by KLN-205 cells as compared to liposomes bearing non-specific isotype-matched antibodies or antibody-free liposomes. Doxorubicin-containing antibody-liposomes resulted in as much as a 15-fold decrease in the 50% inhibitory concentration for doxorubicin against KLN-205 cells as compared to free doxorubicin or doxorubicin entrapped in antibody-free liposomes.
1 This work was supported by the Medical Research Council of Canada (MA-9127).
2 To whom requests for reprints should be addressed.
Received 6/11/92. Accepted 7/17/92.
This article has been cited by other articles:
![]() |
P. Sapra, E. H. Moase, J. Ma, and T. M. Allen Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab' Fragments Clin. Cancer Res., February 1, 2004; 10(3): 1100 - 1111. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Pastorino, C. Brignole, D. Marimpietri, P. Sapra, E. H. Moase, T. M. Allen, and M. Ponzoni Doxorubicin-loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selectively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice Cancer Res., January 1, 2003; 63(1): 86 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-L. Tseng, J.-J. Liu, and R.-L. Hong Translocation of Liposomes into Cancer Cells by Cell-Penetrating Peptides Penetratin and Tat: A Kinetic and Efficacy Study Mol. Pharmacol., October 1, 2002; 62(4): 864 - 872. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Eliaz and F. C. Szoka Jr. Liposome-encapsulated Doxorubicin Targeted to CD44: A Strategy to Kill CD44-overexpressing Tumor Cells Cancer Res., March 1, 2001; 61(6): 2592 - 2601. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |